title: MAP kinase 1/2 (Erk 1/2) and serine/threonine specific protein kinase Akt/PKB expression and activity in the human corpus cavernosum.
abstract: Nitric oxide (NO) is an important mediator in the cavernosal smooth muscle relaxation that causes erections. The purpose of this study was to examine the existence, distribution and phosphorylation stage of two recently discovered key enzymes for NO regulation in human cavernosal tissue, the MAP Kinase 1/2 (Erk 1/2) and the serine/threonine specific protein kinase Akt/PKB. The expression of the enzymes was examined in corpus cavernosum specimens taken from both potent men and from patients with long-term impotence. There was a distinct difference in the activation stage of the MAP Kinase 1/2 (Erk 1/2) between endothelium and smooth muscle cells in potent patients. This finding gives evidence for a cell-type-specific regulation of the eNOS-dependent NO release. Furthermore, we found a higher basal level of active MAP Kinase 1/2 (Erk 1/2) in impotent patients. This finding gives the first evidence for an inhibitory influence of MAP Kinase 1/2 (Erk 1/2) on cavernosal eNOS activity.
authors.affiliation: Department of Urology, University Medical Centre of Cologne, Cologne, Germany. Frank.Sommer@uni-koeln.de
authors.forename: F
authors.initials: F
authors.lastname: Sommer
authors.forename: T
authors.initials: T
authors.lastname: Klotz
authors.forename: D
authors.initials: D
authors.lastname: Steinritz
authors.forename: A
authors.initials: A
authors.lastname: Schmidt
authors.forename: K
authors.initials: K
authors.lastname: Addicks
authors.forename: U
authors.initials: U
authors.lastname: Engelmann
authors.forename: W
authors.initials: W
authors.lastname: Bloch
mesh_terms: D000293:Adolescent; D000328:Adult; D004730:Endothelium, Vascular / Q000201:enzymology; D007172:Erectile Dysfunction / Q000378:metabolism; D006801:Humans; D015151:Immunoblotting; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D019950:Mitogen-Activated Protein Kinase 1 / Q000032:analysis*; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000032:analysis; D009131:Muscle, Smooth, Vascular / Q000201:enzymology; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III; D010413:Penis / Q000098:blood supply / Q000201:enzymology*; D017346:Protein Serine-Threonine Kinases / Q000032:analysis*; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D051057:Proto-Oncogene Proteins c-akt
chemical_list: D011518:Proto-Oncogene Proteins; D009569:Nitric Oxide; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; C494918:AKT1 protein, human; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases